Diagnostic, Therapeutic, and Prognostic Value of the Thrombospondin Family in Gastric Cancer
Yi Lu,Xianhe Kong,Weijie Zhong,Minhui Hu,Chujun Li
DOI: https://doi.org/10.3389/fmolb.2021.647095
IF: 6.113
2021-04-28
Frontiers in Molecular Biosciences
Abstract:Background: Gastric cancer (GC) is the fifth leading cancer in the world. The dysregulated expressions of the thrombospondin (THBS) family were reported to associate with GC, but their relations with tumor stage, prognosis, and correlations with tumor immunity have not been systematically reported. Methods: We used versatile public databases such as Oncomine, GEPIA, UALCAN, Kaplan–Meier Plotter, LinkedOmics, STRING, cBioPortal, TIMER, and TISIDB to analyze the expression and mutations of different THBSs in GC, along with their functional networks, survival analysis, and tumor–immune interactions. Results: The mRNA levels of THBS2 , THBS4, and COMP were significantly higher in the tumor tissues; the expression levels of THBS1 , THBS2 , and THBS4 were higher in stages 2–4 than that of stage 1; patients with high expression of THBS1 , THBS2 , THBS4 , and COMP had poor OS; the genes correlated with THBSs were enriched in focal adhesion, glycosaminoglycan biosynthesis, ECM-receptor interaction, and hedgehog signaling pathway; THBS1 and THBS4 expression had significant correlations with tumor purity, and all the THBSs expression correlated with macrophage and dendritic cells infiltration. Conclusions: THBS2, THBS4, and COMP were potentially diagnostic markers for GC; THBS1, THBS2, THBS4, and COMP were potentially prognostic markers for GC; investigating the relations of THBSs and tumor immunology might help in immunotherapy of GC, while more studies are needed to confirm these results.
biochemistry & molecular biology